Pancytopenia associated with leflunomide and methotrexate [1]

Annals of Pharmacotherapy

Volumn 37, Issue 1, 2003, Pages 149-

  Hill, Richard L ^a   Topliss, Duncan J ^b   Purcell, Patrick M ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b Department of Endocrinology ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; LEFLUNOMIDE; METHOTREXATE;

ADULT; AGED; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; LATENT PERIOD; LETTER; MALE; PANCYTOPENIA; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; RISK;

EID: 0037224358     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C293     Document Type: Letter

References (5)

1. Auer J, Hinterreiter M, Allinger S, Kirchgatterer A, Knoflach P. Severe pancytopenia after leflunomide in rheumatoid arthritis. Acta Med Austriaca 2000;27:131-2.
2. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): Clinical pathology and general disorders. Pharmacoepidemiol Drug Saf 1999:8:217-24.
3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
4. Buchbinder R, Hall S, Sambrook PN, Champion DG, Harkness A, Lewis D, et al. Methotrexate therapy in rheumatoid arthritis: A life table review of 587 patients treated in community practice. J Rheumatol 1993;20:639-44.
5. Morgan SL, Baggot JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.